GSK’s Jemperli approved for advanced endometrial cancer in Singapore

GSK Singapore obtained the Singapore HSA approval for a new indication for Jemperli for advanced or recurrent endometrial cancer.

Related Posts

Agios sells vorasidenib US royalties for $905m

May 31, 2024

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

Oct 12, 2024

CHMP provides positive opinion for BMS’s Reblozyl

Feb 24, 2024